114 related articles for article (PubMed ID: 38583812)
1. Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells.
Sang J; Liu CK; Liu J; Luo GC; Zheng WJ; Bai Y; Jiang DY; Pu JN; An S; Xu TR
Biochem Pharmacol; 2024 May; 223():116194. PubMed ID: 38583812
[TBL] [Abstract][Full Text] [Related]
2. Jolkinolide B targets thioredoxin and glutathione systems to induce ROS-mediated paraptosis and apoptosis in bladder cancer cells.
Sang J; Li W; Diao HJ; Fan RZ; Huang JL; Gan L; Zou MF; Tang GH; Yin S
Cancer Lett; 2021 Jul; 509():13-25. PubMed ID: 33836250
[TBL] [Abstract][Full Text] [Related]
3. Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy.
Sang J; Gan L; Zou MF; Lin ZJ; Fan RZ; Huang JL; Li W; Tang GH; Yin S
Cancer Lett; 2022 Feb; 526():352-362. PubMed ID: 34798195
[TBL] [Abstract][Full Text] [Related]
4. Curcuminoid WZ35 synergize with cisplatin by inducing ROS production and inhibiting TrxR1 activity in gastric cancer cells.
He W; Xia Y; Cao P; Hong L; Zhang T; Shen X; Zheng P; Shen H; Liang G; Zou P
J Exp Clin Cancer Res; 2019 May; 38(1):207. PubMed ID: 31113439
[TBL] [Abstract][Full Text] [Related]
5. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
6. ML162 derivatives incorporating a naphthoquinone unit as ferroptosis/apoptosis inducers: Design, synthesis, anti-cancer activity, and drug-resistance reversal evaluation.
Ma F; Li Y; Cai M; Yang W; Wu Z; Dong J; Qin JJ
Eur J Med Chem; 2024 Apr; 270():116387. PubMed ID: 38593589
[TBL] [Abstract][Full Text] [Related]
7. Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.
Zhang H; Wu J; Yuan J; Li H; Zhang Y; Wu W; Chen W; Wang C; Meng S; Chen S; Huo M; He Y; Zhang C
J Exp Clin Cancer Res; 2021 Aug; 40(1):260. PubMed ID: 34412665
[TBL] [Abstract][Full Text] [Related]
8. Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe
Ni M; Zhou J; Zhu Z; Xu Q; Yin Z; Wang Y; Zheng Z; Zhao H
Phytomedicine; 2023 Apr; 112():154701. PubMed ID: 36773431
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SND1 overcomes chemoresistance in bladder cancer cells by promoting ferroptosis.
Zhao Y; Ren P; Yang Z; Wang L; Hu C
Oncol Rep; 2023 Jan; 49(1):. PubMed ID: 36453257
[TBL] [Abstract][Full Text] [Related]
10. Yi-qi-hua-yu-jie-du decoction induces ferroptosis in cisplatin-resistant gastric cancer via the AKT/GSK3β/NRF2/GPX4 axis.
Huang W; Wen F; Yang P; Li Y; Li Q; Shu P
Phytomedicine; 2024 Jan; 123():155220. PubMed ID: 38056149
[TBL] [Abstract][Full Text] [Related]
11. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine.
Anestål K; Arnér ES
J Biol Chem; 2003 May; 278(18):15966-72. PubMed ID: 12574159
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of thioredoxin reductase and proteasome is required for auranofin-induced paraptosis in breast cancer cells.
Seo MJ; Kim IY; Lee DM; Park YJ; Cho MY; Jin HJ; Choi KS
Cell Death Dis; 2023 Jan; 14(1):42. PubMed ID: 36658130
[TBL] [Abstract][Full Text] [Related]
13. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
[TBL] [Abstract][Full Text] [Related]
14. High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy.
Eriksson SE; Prast-Nielsen S; Flaberg E; Szekely L; Arnér ES
Free Radic Biol Med; 2009 Dec; 47(11):1661-71. PubMed ID: 19766715
[TBL] [Abstract][Full Text] [Related]
15. Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells.
Chen X; Chen X; Zhang X; Wang L; Cao P; Rajamanickam V; Wu C; Zhou H; Cai Y; Liang G; Wang Y
Redox Biol; 2019 Feb; 21():101061. PubMed ID: 30590310
[TBL] [Abstract][Full Text] [Related]
16. Nitrovin (difurazone), an antibacterial growth promoter, induces ROS-mediated paraptosis-like cell death by targeting thioredoxin reductase 1 (TrxR1).
Zhao L; Zhong B; Zhu Y; Zheng H; Wang X; Hou Y; Lu JJ; Ai N; Guo X; Ge W; Ma YY; Chen X
Biochem Pharmacol; 2023 Apr; 210():115487. PubMed ID: 36893814
[TBL] [Abstract][Full Text] [Related]
17. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y
Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669
[TBL] [Abstract][Full Text] [Related]
18. Novel Covalent Probe Selectively Targeting Glutathione Peroxidase 4 In Vivo: Potential Applications in Pancreatic Cancer Therapy.
Tang Z; Li J; Peng L; Xu F; Tan Y; He X; Zhu C; Zhang ZM; Zhang Z; Sun P; Ding K; Li Z
J Med Chem; 2024 Feb; 67(3):1872-1887. PubMed ID: 38265413
[TBL] [Abstract][Full Text] [Related]
19. Plumbagin reduction by thioredoxin reductase 1 possesses synergy effects with GLUT1 inhibitor on KEAP1-mutant NSCLC cells.
Sun S; Zhang Y; Xu W; Yang R; Yang Y; Guo J; Ma Q; Ma K; Zhang J; Xu J
Biomed Pharmacother; 2022 Feb; 146():112546. PubMed ID: 34954641
[TBL] [Abstract][Full Text] [Related]
20. EF24 induces ROS-mediated apoptosis via targeting thioredoxin reductase 1 in gastric cancer cells.
Zou P; Xia Y; Chen W; Chen X; Ying S; Feng Z; Chen T; Ye Q; Wang Z; Qiu C; Yang S; Liang G
Oncotarget; 2016 Apr; 7(14):18050-64. PubMed ID: 26919110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
